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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
rivastigmine is effective for the treatment of Alzheimer’s Disease. 
STUDY DESIGN: Review of two trials in the English language published in 2007 and 2010, and 
an open-label, singlearm, multi-center study from 2008. 
DATA SOURCES: Randomized, double-blind, placebo-controlled trials comparing rivastigmine 
to a visually-matched capsule (placebo) was found using PubMed and Cochrane databases.    
OUTCOMES MEASURED: Overall global performance using the Alzheimer’s Disease 
Assessment Scale (ADAS-cog), ability to perform activities of daily living, cognitive function 
using the mini mental status exam (MMSE), and neuropsychiatric symptoms using BEHAVE-
AD. 
RESULTS: The two RCTs included in the review along with the open-label study showed that 
rivastigmine did help improve symptoms, but usually in patients with a more severe or 
progressive form of dementia. Rivastigmine was also shown to be more effective in preventing 
cognitive decline when given at higher doses and to participants who did not have other 
confounding symptoms, such as hallucinations.  
CONCLUSIONS:  The results of the RCTs and open-label study show that rivastigmine for the 
treatment of Alzheimer’s disease is safe and effective.  
KEYWORDS: Alzheimer’s disease, rivastigmine, treatment 
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INTRODUCTION 
 Alzheimer’s disease is a neurological condition that consists of a decline in cognition, 
memory and activities of daily living. Memory loss tends to involve an impaired recall of 
previously learned information. The two hallmark findings in brains affected by Alzheimer’s are 
intracellular neurofibrillary tangles from the clump of hyperphosphorylated tau proteins and the 
extracellular senile plaques, which are made of amyloid beta protein. It has been estimated that 1 
new case of AD develops every 7 seconds, with an even higher rate in developing countries.4 
More than 5 million Americans and over 10% of American citizens who are 71 years of age or 
older suffer from AD and the medical needs of patients affected by AD continue to be unmet. 
Care-givers for individuals with AD spend greater than $94 billion dollars annually on AD-
related healthcare costs.4  
While research is still searching for ways to detect Alzheimer’s disease in individuals 
before progressive cognitive decline starts to become an issue, there is still no surefire way of 
preventing the inevitable from happening in people who are affected by the disease. The global 
cognitive status of individuals is assessed using questionnaires, such as the Mini Mental Status 
Exam (MMSE), Alzheimer’s disease assessment scale-cognitive subscale (ADAS-cog) and 
Behavioral Pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD).1,2 Hallucinations are 
a common finding in individuals affected by the disease and they are present in 20% to 40% of 
patients, with visual hallucinations being the most common form.1 Current treatment includes 
acetylcholinesterase inhibitors, such as donepezil, galantamine and rivastigmine, in patients with 
mild to moderate AD.5 Individuals with more advanced disease have shown to have some 
benefits from memantine alone, which is an N-methyl-D-aspartate antagonist.5 Caregiver support 
and respite care are often necessary as well in order to help the individuals carry out their normal 
activities of daily living.  
Rivastigmine has been proposed as an effective treatment for Alzheimer’s disease by 
reducing neuropsychiatric symptoms in patients with AD who have hallucinations as well as 
patients who are unresponsive to other treatments1. In one study, it was demonstrated that 
switching from donepezil to rivastigmine without a washout period may still be well-tolerated 
and effective in patients who do not improve with donepezil.3  
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OBJECTIVE: 
 The objective of this systematic review is to determine whether or not rivastigmine is 
effective for the treatment of Alzheimer’s Disease. Previous trials in this study that have studied 
the efficacy of rivastigmine in treating the neuropsychiatric symptoms of Alzheimer’s disease 
have shown that it is a safe and effective alternative to other medications, such as donepezil.  
METHODS: 
The studies that were obtained for this analysis included individuals who were 45 years 
of age and older with a clinical diagnosis of Alzheimer’s disease. The intervention that was used 
was 1 to 12 mg of rivastigmine. Comparisons to this intervention included a visually matched 
placebo group. The outcomes measured were overall global performance using the Alzheimer’s 
Disease Assessment Scale (ADAS-cog), ability to perform activities of daily living, cognitive 
function using the mini mental status exam (MMSE), and neuropsychiatric symptoms using 
BEHAVE-AD. The types of studies included in this systematic review are two double-blind, 
placebo-controlled randomized controlled trials and an open-label, singlearm, multicenter study.  
Information on these studies was gathered from databases such as Cochrane Database of 
Systematic Reviews, MEDLINE and PubMed. The articles were selected based upon their 
relevance to the question and significance of the outcomes to the patients. Inclusion criteria that 
were used for the selection of studies included: 1) Studies that were randomized controlled trials. 
2) Studies that consisted of patient-oriented outcomes (POEMs). 3) Studies published after 1996. 
4) Studies published in the English language. Exclusion criteria used to limit the selection of 
studies included: 1) Articles that were systematic reviews. 2) Subjects who did not fulfill the 
criteria for diagnosis of dementia of the Alzheimer’s type. While searching for studies in the 
English language, specific keywords that were used included “Alzheimer’s disease,”  
“rivastigmine” and “treatment.” This helped to selectively limit articles that held more 
significance and were more pertinent to the study. The studies that were then finalized and 
selected were: 1) Effects of rivastigmine in Alzheimer's disease patients with and without 
hallucinations, 2) Rivastigmine: a placebo controlled trial of twice daily and three times daily 
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regimens in patients with Alzheimer's disease, and 3) Safety and efficacy of rivastigmine in 
patients with Alzheimer's disease not responding adequately to donepezil: an open-label study. 
The characteristics of all the studies that were used in this analysis can be found in Table 1.  
Table 1: Demographics and Characteristics of included studies 
Study Type # pts Age Inclusion Criteria Exclusion Criteria # of withdrawal  Interventions 
Feldma
n2, 
2007 
Double-
blind, 
placebo-
controlled 
RCT   
678 At least 50 
years of age 
Entry scores of 10-
26 on the MMSE 
and met the criteria 
for AD 
Concomitant 
severe/unstable 
cardiac disease, 
severe obstructive 
pulmonary disease or 
life-threatening 
conditions; anti-
cholinergic drugs 
125 Rivastigmine twice a 
day or three times a 
day with a range of 
dosing between 2-12 
mg/day; placebo 
Cummi
ngs1 
2010 
Double-
blind, 
placebo-
controlled 
RCT   
927 Between the 
ages of 45 and 
89 years old  
Met criteria for AD, 
score between 10 
and 26 on MMSE; 
concomitant 
controlled and 
manageable 
illnesses; with or 
without 
hallucinations 
Other dementias; 
severe cardiac 
disease and 
obstructive 
pulmonary disease; 
malignancies; 
psychotropic drugs; 
anti-cholinergic drugs 
225 6-month trials of 
rivastigmine capsules 
with flexible dosing up 
to 12 mg/day in 2 
divided daily doses 
Figiel3, 
2008 
Open-
label, 
single-arm 
study 
270 Between ages 
of 50 and 90 
Diagnosis of 
dementia of 
Alzheimer’s type; 
MMSE score of 10 
to 26; prior use of 
donepezil 10 
mg/day for at least 
3 months prior to 
baseline with poor 
results; concomitant 
major depression  
advanced medical 
illnesses; CVA 6 
months prior to 
baseline; 
uncontrolled seizure 
disorder; unstable 
asthma or obstructive 
pulmonary disease; 
medications for 
parkinson’s disease 
or anticholinergics; 
lithium; previous 
exposure to 
rivastigmine 
85 26-week treatment 
period with 
rivastigmine and 
flexible dosing of 3-12 
mg/day 
 
Beena Patel 
Rivastigmine & Alzheimer’s Disease 5 
 
 
Outcomes that were measured were POEMs, such as the efficacy of medication 
(rivastigmine) in treating Alzheimer’s disease along with the amount or dosage of medication 
used, changes in activities of daily living using the PDS, current cognitive function using the 
MMSE, ability to perform activities of daily living by the use of ADAS-cog, and the severity of 
neuropsychiatric symptoms using BEHAVE-AD. The Progressive Deterioration Scale (PDS) 
measures the changes in activities of daily living. There is a 29-item scale scored on a scale of 0 
to 100, where an increase in score suggests an improvement in the patient’s ability to perform 
activities of daily living. The Mini Mental Status Exam (MMSE) assesses memory, attention, 
concentration, repetition, comprehension and ability to create a sentence. It includes a 10-item 
assessment, with a range of 0-30 points in which a higher score represents better cognitive 
function. The Alzheimer’s Disease Assessment Scale (ADAS-cog) has a total score range of 0-
70, where a decreasing score shows improvement in cognitive function. Neuropsychiatric 
symptoms were obtained using the Behavioral Pathology in Alzheimer’s Disease Rating Scale 
(BEHAVE-AD), which is a 25-item scale that evaluates paranoid and delusional ideation (7 
items), hallucinations (5 items), activity disturbances (3 items), aggressiveness (3 items), diurnal 
rhythm disturbances (1 item), affective disturbance (2 items), and anxieties and phobias (4 
items). The items are then rated on a four-point scale (0-3) based on a clinical interview with a 
caregiver, with the scores assigned depending on the severity of symptoms that are observed (A 
score of 0 in a specific item signifies the absence of a symptom while a score of 3 represents the 
most severe category).  
RESULTS: 
 The results of this review were presented as continuous data. The data in the Feldman et 
al and Cummings et al studies can be converted to dichotomous form. The data from all the 
studies were analyzed with the intention to treat, excluding those who withdrew from the study.  
The inclusion and exclusion criteria were fairly similar for each of the studies. The participants 
for all the studies consisted of individuals who were 45 years of age and older with a clinical 
diagnosis of Alzheimer’s Disease.  The studies excluded participants who did not fit the criteria 
for diagnosis of dementia of the Alzheimer’s type and individuals who had an advanced, severe, 
or unstable medical condition of any type that could possibly interfere with the assessment. 
Patients with a cerebrovascular accident within six months of baseline, uncontrolled peptic 
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ulcers, severe or unstable asthma or obstructive pulmonary disease, any psychiatric diagnosis 
that could interfere with the response of patient to study medication, and uncontrolled active 
seizure disorders were excluded as well.  
 The study done by Figiel et al studied Rivastigmine in patients who did not respond well 
to prior use of donepezil. The study reported that out of 226 patients with a minimum of 1 
neuropsychiatric inventory symptom at baseline, 42.0% showed greater than 30% improvement. 
The mean MMSE score from baseline was 18.2. The primary analysis was done at 26 weeks, 
where changes in efficacy from baseline were tested using paired t-tests, where a p-value < 0.05 
was found to be significant. The 95% confidence interval included the percept of participants 
who showed improvement or no changes from baseline on the CGIC scale.3  
 In the study done by Feldman et al, Rivastigmine was given in a dose of 9.6 mg/day in 
the TID regimen compared to 8.9 mg/day in the BID regimen. While both regimens were shown 
to be beneficial to the cognitive performance in patients with Alzheimer’s disease, the TID 
regimen demonstrated to have an even higher tolerability and was clinically effective with higher 
doses, further showing that the efficacy of rivastigmine may be a result of its dose. The relative 
benefit increase (RBI) was 63.2% and the absolute benefit increase (ABI) was 12%. The number 
needed to treat (NNT) was 9 patients. 9 people, thus, needed to be treated with rivastigmine in 
order to prevent cognitive decline in one patient with AD. The difference in the control and 
experimental group is statistically significant with the p-value less than 0.05.2 
 In the study done by Cummings et al, rivastigmine was clinically more effective in 
participants without hallucinations in comparison to those with hallucinations. The number 
needed to treat (NNT) was 12 patients. In those participants with hallucinations, for every one 
person treated, one less person would benefit from the treatment. On the other hand, 12 people 
need to be treated in the non-hallucinating group in order to improve the cognitive function of 
one individual. The relative benefit increase (RBI) in persons without hallucinations was 
0.0035% and the absolute benefit increase (ABI) was 0.2%. The difference between the control 
and experimental groups is statistically significant with the p-value less than 0.05. Table 2 shows 
a summary of the three studies and the results for the efficacy of rivastigmine in the treatment of 
Alzheimer’s disease.1  
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Table 2. Clinical efficacy of Rivastigmine in the treatment of Alzheimer’s Disease 
 
RBI= Relative Benefit Increase, ABI= Absolute Benefit Increase, NNT= Number Needed to 
Treat, 
NR= Not Reported 
 Each study also calculated the incidence of adverse effects regarding the safety of 
rivastigmine usage. In the study done by Feldman et al, the incidence of adverse events was 18% 
for the rivastigmine TID group, 76.2% in the BID group and 91.6% in the placebo group. The 
relative risk increase (RRI) was -16.9% and the absolute risk increase (ARI) was -15.5%. The 
number needed to harm (NNH) was 7 patients. If 7 participants are treated with rivastigmine, one 
less person would have a beneficial outcome, suggesting that the intervention may be harmful. 
Common adverse effects reported with use of rivastigmine included nausea, vomiting, anorexia 
and abdominal pain.2  
 The study conducted by Cummings et al showed 93% of individuals using rivastigmine 
compared to 78% of participants in the placebo group faced at least one adverse event. The 
relative risk increase (RRI) was 0.19% and the absolute risk increase (ARI) was 0.15%. The 
number needed to harm (NNH) was 7 patients.1  
Study Rivastigmine 
group 
Individuals with 
improvement of 
cognitive 
performance 
Control group 
Individuals with 
improvement of 
cognitive 
performance 
p-value RBI ABI NNT 
Feldman et 
al, 2007 
31% 19% p < 0.05 63.2% 12% 9 
Cummings 
et al, 2010 
36% 27% p ≤ 0.05 0.0035% 0.2% 12 
Figiel et al, 
2008 
42.0% NR p ≤ 0.05 NR NR NR 
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 The Figiel et al study indicated that the incidence of adverse effects in the rivastigmine 
group was 82.6%. The data in this study was statistically significant with a p-value of ≤ 0.05. 
Table 3 shows a summary of the incidence of adverse effects in patients in the rivastigmine 
group and in the control group for each study performed.3  
Table 3 – Incidence of Adverse Events of Rivastigmine and Control Groups 
Study Rivastigmine 
Incidence of 
Adverse 
Events 
Control 
Group 
Incidence of 
Adverse 
Events 
p-value RRI ARI NNH 
Feldman et 
al, 2007 
76.2% 91.6% p < 0.05 -16.9% -15.5% -7 
Cummings 
et al, 2010 
93% 78% p ≤ 0.05 0.19% 0.15% 7 
Figiel et al, 
2008 
82.6% NR p ≤ 0.05 NR NR NR 
 RRI= Relative Risk Increase, ARI= Absolute Risk Increase, NNH= Number Needed to Harm, 
NR= Not Reported 
 In all three studies investigated with rivastigmine, the most common adverse effects 
usually pertained to gastrointestinal symptoms, such as nausea, vomiting, abdominal pain and 
loss of appetite.  In all three studies, the incidence of adverse effects reported was higher in the 
rivastigmine group. Table 4 shows the incidence of gastrointestinal events that happened during 
the Cummings et al study on rivastigmine.1  
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Table 4. Incidence of GI adverse effects in Rivastigmine and Placebo Groups  
Gastrointestinal 
Adverse Event 
Rivastigmine 
n=356 
Placebo 
n=376 
Nausea 52 12 
Vomiting 33 5 
Abdominal Pain 12 6 
n = number of participants in the group 
DISCUSSION: 
 The Figiel et al study did not consist of a placebo or control group because there were 
ethical concerns of not providing treatment to participants who were already responding poorly 
to donepezil. However, not having a control group could have limited the findings and 
conclusions. Participants in a placebo group may still have deteriorated but at a slower rate. It is 
difficult to make conclusions about efficacy due to the lack of randomization and a control 
group. Results suggest that 50 to 70% of participants who did not respond to donepezil may still 
have shown stabilization or improvement in cognitive function with rivastigmine. Therefore, 
when switching a patient from donepezil to rivastigmine, the individual’s behavioral 
performance should be taken into account as well and not just his/her cognitive and global 
performance. In addition, there was an overall completion rate of 69% in the study, which is 
debatable in terms of the true efficacy and tolerability of rivastigmine.3 Researchers found that it 
is clinically possible to switch patients from donepezil to rivastigmine without a washout period 
(which was done in earlier trials) in order to maintain the treatment effect; this finding was taken 
into account later on in the study.     
 In the study conducted by Cummings et al, there were some discrepancies with the 
efficacy of rivastigmine in individuals affected by AD who had hallucinations versus those who 
did not have hallucinations. Further studies have shown that rivastigmine allows for a more 
significant benefit in patients who have a more severe or progressive form of dementia.1 That 
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may play a role as to why there were larger placebo differences observed in groups with greater 
cognitive decline. However, this may hold some significance because other studies have shown 
that the cholinesterase-inhibiting activity of rivastigmine plays a central role in reducing severe 
neuropsychiatric symptoms; this is very helpful for researchers to be aware of because 
Alzheimer’s disease has been linked to a reduction in the activity of cholinergic neurons.   
 In the Feldman et al study, rivastigmine caused a small but statistically significant 
decrease in the average weight in both the TID and BID groups. This led to a decrease in heart 
rate of individuals in both groups compared to the placebo—this may have altered the efficacy of 
rivastigmine. Furthermore, there were about 33% of subjects in the TID group who were 
receiving less than 6 mg/day during withdrawal due to adverse events and an estimated 66% 
were taking at least 6 mg/day while, in the BID group, about 50% were taking at least or less 
than 6 mg/day so the higher rate of discontinuation or withdrawal in the BID group does not 
necessarily reflect higher doses taken in this group and so, the reasons for discontinuation remain 
unknown.2 This could have altered the significance of the findings. Additionally, although the 
maximally tolerated mean dose was higher for individuals in the TID group, it was noted that 
rivastigmine with food or shortly after a meal can improves its tolerability by reducing peak 
plasma concentrations of the drug and slowing its rate of increase so this could have played a 
role in efficacy. Also, since the drug is rapidly absorbed by the gastrointestinal tract, some 
patients may have not been as compliant with proper drug usage in order to avoid symptoms of 
nausea and vomiting. 
CONCLUSIONS: 
 The trials that were reviewed suggest that rivastigmine is safe and effective for the 
treatment of Alzheimer’s disease. The individuals of the studies seemed to show improvement 
with activities of daily living and a higher cognitive function according to the higher scores on 
the MMSE. Some flaws include the length of treatment, which may not have been as long of a 
duration to really assess whether rivastigmine is, in fact, effective in reducing the long-term 
cognitive decline associated with Alzheimer’s disease. Studies in the future should include 
various medications to compare rivastigmine with and investigate the overall results and adverse 
effects over a more extended period of time. This, in turn, may allow future healthcare 
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professionals to have a better stance on what drugs may be more appropriate for their patient 
population and their associated symptoms. The outcomes of these future studies may help 
determine what may be the best pharmacological treatment of Alzheimer’s disease.  
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